UNITED BIOTECH (P) LTD.
Streptokinase Injection IP

Streptokinase Injection IP

Send Inquiry

Streptokinase Injection IP

Indications :

Acute Myocardial Infarction: Less than 12 hours        
Deep Venous Thrombosis: Less than 14 days           
Acute Massive Pulmonary Embolism           
Acute Arterial Thrombosis and Embolism           
Clotting in Haemodialysis Shunts


Dosage :

*STREPTONASE-R should be administered as soon as possible after onset of symptoms of myocardial infarction. The greatest benefit in mortality reduction is achieved when Streptokinase is administered within the first 6 hours but substantial benefit has been demonstrated at up to 12 hours.

**Administered for up to 3 days. If possible an angiographic assessment should then be performed. If no clinical effect is noted after 3 days, treatment should be discontinued.

*** Follow-up Treatment: After every course of recombinant streptokinase therapy, a follow-up treatment with anticoagulants or platelet aggregation inhibitors can be instituted as a prevention of rethrombosis. With heparin therapy in particular an increased risk of haemoglobin must be considered.

STREPTONASE-R therapy may otherwise be continued for an additional 1-3 days if considered necessary.

 

We also deals in:

Name of the Product Composition
Streptonase-R 15 Recombinant Streptokinase 15LIU